TLR9 and melanoma: Recent studies using the melanoma mouse model demonstrated that JAK1/2 knockout resistance could be overcome with anti-PD-1 Ab in combination with the TLR9 agonist, which activates TLR9-type IFN signaling, thereby increasing infiltration of T cells and NK cells in the tumor (39).